ON THIS PAGE: You will read about the scientific research being done now to learn more about this type of cancer and how to treat it. To see other pages in this guide, use the colored boxes on the right side of your screen, or click “Next” at the bottom.
Research for AdCC is ongoing. The following advances may still be under investigation in clinical trials and may not be approved or available at this time. Always discuss all diagnostic and treatment options with your doctor.
Anti-angiogenesis research. Anti-angiogenesis therapy is a type of targeted therapy (see below). It is focused on stopping angiogenesis, which is the process of making new blood vessels. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumor. Research is focused on how this type of therapy may benefit patients with AdCC.
Targeted therapies. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Currently, targeted therapies are being developed that may be useful in the treatment of AdCC. In particular, research continues to determine the molecular mechanism that regulates the spread of AdCC along the nerves. Learn more about targeted treatments.
Chemotherapy. Several clinical trials are examining the effects of newer drugs alone, or in combination with other drugs, in the control of metastatic or locally recurrent AdCC.
Supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current AdCC treatments in order to improve patients’ comfort and quality of life.
To find clinical trials specific to your diagnosis, talk with your doctor or search online clinical trial databases now
To continue reading this guide, choose “Next” (below, right) to see a section about coping with the side effects of the disease or its treatment. Or, use the colored boxes located on the right side of your screen to visit any section.